63-92-3

基本信息
鹽酸苯氧芐胺
鹽酸酚芐明
苯芐胺
苯氧芐胺
酚芐胺
竹林胺
鹽酸酚芬明
酚芐明
BENZENE METHANAMINE HYDROCHLORIDE
DIBENZYLINE HYDROCHLORIDE
n-(2-chloroethyl)-n-(1-methyl-2-phenoxyethyl)benzenemethanamine hydrochloride
N-(2-CHLOROETHYL)-N-(1-METHYL-2-PHENOXYETHYL)BENZYLAMINE HYDROCHLORIDE
N-PHENOXYISOPROPYL-N-BENZYL-2-CHLOROETHYLAMINE HYDROCHLORIDE
PHENOXYBENZAMINE
PHENOXYBENZAMINE HCL
PHENOXYBENZAMINE HYDROCHLORIDE
bensylytnen
benzyl(2-chloroethyl)(1-methyl-2-phenoxyethyl)aminehydrochloride
dibenzyran
fenossibenzamina
fenoxybenzamin
n-(2-chloroethyl)-n-(1-methyl-2-phenoxyethyl)-benzenemethanaminhydrochlo
n-(2-chloroethyl)-n-(1-methyl-2-phenoxyethyl)-benzylaminhydrochloride
n-2-phenoxyisopropyl-n-benzyl-chloroethylaminehydrochloride
n-benzyl-n-phenoxyisopropyl-beta-chlorethylaminehydrochloride
nci-c01661
n-phenoxyisopropyl-n-benzyl-beta-chloroethylaminehydrochloride
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
制備方法
![2-[benzyl(1-methyl-2-phenoxyethyl)amino]ethanol](/CAS/GIF/101-45-1.gif)
101-45-1

63-92-3
在25-30℃條件下,將N-(苯氧基異丙基)-N-芐基乙醇胺溶解于二氯甲烷(810 mL)中。隨后,在0-5℃下緩慢滴加亞硫酰氯(70.0 g, 0.588 mol)。反應(yīng)混合物于25-30℃持續(xù)攪拌2小時。反應(yīng)完成后,于30-35℃下進(jìn)行減壓濃縮。將濃縮后的殘余物于25-30℃溶解于丙酮(570 mL)中,促使固體形成。通過過濾收集固體,并用冷卻的丙酮(190 mL)洗滌。最后,將固體于45-50℃下進(jìn)行真空干燥,得到125.4 g高純度的苯氧基苯甲胺鹽酸鹽,呈白色固體(HPLC純度 > 99%)。
參考文獻(xiàn):
[1] Patent: WO2018/130942, 2018, A1. Location in patent: Page/Page column 10; 12
報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
2025/05/22 | HY-B0431A | 鹽酸酚芐明 Phenoxybenzamine hydrochloride | 63-92-3 | 500mg | 300元 |
2025/05/22 | S2499 | 鹽酸酚芐明 Phenoxybenzamine HCl | 63-92-3 | 50mg | 788.04元 |
2025/05/22 | HY-B0431A | 鹽酸酚芐明 Phenoxybenzamine hydrochloride | 63-92-3 | 10mM * 1mLin DMSO | 330元 |
常見問題列表
Target | Value |
α-adrenergic receptor |
The IC 50 (100 nM) derived from the blockade of [ 3 H]yohimbine binding by Phenoxybenzamine hydrochloride is significantly less than the IC 50 (550 nM) for the corresponding reversal by Phenoxybenzamine hydrochloride of the effects of norepinephrine on cyclic AMP accumulation. Phenoxybenzamine hydrochloride (50 nM) in conbination with Phenoxybenzamine hydrochloridetolamine (1000 nM) enhances Phenoxybenzamine hydrochlorideylephrine-induced contraction compared with pretreatment with Phenoxybenzamine hydrochloride (50 nM) alone in endothelium-intact aortae. Combined treatment with either dexmedetomidine (300 or 1000 nM) and Phenoxybenzamine hydrochloride (50 nM) or Phenoxybenzamine hydrochloridetolamine (1000 nM) and Phenoxybenzamine hydrochloride (50 nM) enhance Phenoxybenzamine hydrochlorideylephrine-induced contraction compared with Phenoxybenzamine hydrochloride alone (50 nM). In addition, combined treatment with Phenoxybenzamine hydrochloridetolamine and Phenoxybenzamine hydrochloride enhances Phenoxybenzamine hydrochlorideylephrine-induced contraction compared with dexmedetomidine (1000 nM) and Phenoxybenzamine hydrochloride combined treatment. ?Combined treatment with high concentrations of dexmedetomidine (1000 nM) and Phenoxybenzamine hydrochloride enhances Phenoxybenzamine hydrochlorideylephrine-induced contraction compared with combined treatment with low concentrations of dexmedetomidine (300 nM) and Phenoxybenzamine hydrochloride. Phenoxybenzamine hydrochloride (0.1-100 μM) inhibits glioma proliferation, migration, and invasion and suppresses the tumorigenesis capacity. Phenoxybenzamine hydrochloride also inhibits self-renewal of glioma stem-like cells. Phenoxybenzamine hydrochloride activates LINGO-1 and inhibits the TrkB-Akt pathway. Phenoxybenzamine hydrochloride (0.1 μM-1 mM) preserves primary neurons within the CA1, CA3 and dentate gyrus and produces a robust neuroprotective effect, and prevents neuronal death from OGD in all regions of the hippocampus when delivered at 2, 4, and 8 h post-OGD at 100 μM.
Phenoxybenzamine hydrochloride (20 nM, s.c.) effectively suppresses the tumorigenesis of glioma cells in mice and the cell density in Phenoxybenzamine hydrochloride-U87MG xenografts decreases significantly. Phenoxybenzamine hydrochloride (1 mg/kg, i.v.) treated rats shows significant improvements in NSS and foot fault scoring.